Home > Insider Trading > Filing (0001144204-18-014729)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1023024	Ani Pharmaceuticals Inc	ANIP	Pharmaceutical Preparations (2834)	582301143

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1268135	Arthur Przybyl	C/O Ani Pharmaceuticals, Inc. 210 Main Street West Baudette MN 56623	President And Ceo	Yes	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2018-03-12	15,723	$6.36	225,706	No	4	M	Direct
Common Stock	Disposition	2018-03-13	23,475	$61.52	202,231	No	4	S	Direct
Common Stock	Disposition	2018-03-13	6,525	$62.63	195,706	No	4	S	Direct
Common Stock	Disposition	2018-03-14	10,000	$62.03	185,706	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	M	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Stock Option	Disposition	2018-03-12	15,723	$0.00	15,723	$6.36

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
0		2023-07-11	No	4	M	Direct

Footnotes

This transaction was executed in multiple trades at prices ranging from $61.11 to $62.10. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
This transaction was executed in multiple trades at prices ranging from $62.12 to $63.12. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
This transaction was executed in multiple trades at prices ranging from $62.00 to $62.23. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
The options vested and become exercisable in equal annual amounts over a four-year period beginning on the first anniversary of the grant date. The grant date was July 12, 2013.